Report #2835200

Overview

Sex

Male

Age

Age unknown

State

FL

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (1)

Symptom narrative

received a dose of Priorix via intramuscular instead of subcutaneous; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a male patient who received MMR (Priorix) for prophylaxis. On an unknown date, the patient received Priorix (intramuscular). On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: received a dose of Priorix via intramuscular instead of subcutaneous). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 27-MAR-2025 The pharmacist reported that two patients received a dose of Priorix via intramuscular instead of subcutaneous which led to subcutaneous injection formulation administered by other route. The Vaccine Administration Facility was the same as Primary Reporter.